CheckMate 8HW: Nivolumab Plus Ipilimumab Versus Chemotherapy for Metastatic Colorectal Cancer
By Thierry André, MD - Last Updated: March 19, 2025Dr. Thierry André from Hôpital Saint-Antoine gives an overview of the CheckMate 8HW study that compared nivolumab plus ipilimumab against chemotherapy for patients with microsatellite instability–high or mismatch repair deficient metastatic colorectal cancer. The combination showed significant improvement in progression-free survival in patients in the first line setting.
Advertisement
Advertisement
Related Posts
Dr. Christopher Lieu shares his top liver-directed therapies for metastatic colorectal cancer with liver involvement.
Dr. Christopher Lieu shares his list of top targeted therapies for metastatic colorectal cancer.
The DYNAMIC study began in 2015 to analyze the efficacy of ctDNA in guiding the use of adjuvant chemotherapy.
Dr. Alan Venook reflects on how his leadership roles have shaped his collaborative approach to cancer research and treatment.
Sotorasib plus panitumumab may prolong progression-free survival in patients with KRAS G12C mCRC.
630 Madison Ave.
Manalapan, NJ 07726
About Column
Contribute Column
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.